Though this has somewhat overshadowed the use of immunoblocking antibodies as therapeutic agents for IBD and CRC, studies into anti-VCAM-1 antibody mechanisms and efficacy still provide significant insights into cell adhesion-targeting strategies in colonic diseases. The gene discussed is VCAM1; the disease is colorectal carcinoma.